0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-8S14036
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Proliferative Vitreoretinopathy PVR Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Research Report 2025

Code: QYRE-Auto-8S14036
Report
September 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Proliferative Vitreoretinopathy (PVR) Therapeutics Market

Proliferative Vitreoretinopathy (PVR) Therapeutics Market

The global market for Proliferative Vitreoretinopathy (PVR) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Proliferative Vitreoretinopathy (PVR) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proliferative Vitreoretinopathy (PVR) Therapeutics.
The Proliferative Vitreoretinopathy (PVR) Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Proliferative Vitreoretinopathy (PVR) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Proliferative Vitreoretinopathy (PVR) Therapeutics Market Report

Report Metric Details
Report Name Proliferative Vitreoretinopathy (PVR) Therapeutics Market
CAGR 5%
Segment by Type
  • PRM-167
  • XOMA-089
  • Others
Segment by Application
  • Hospital
  • Clinic
  • ASCs
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis AG, Promedior Inc, RXi Pharmaceuticals Corp
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Proliferative Vitreoretinopathy (PVR) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market report?

Ans: The main players in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market are Novartis AG, Promedior Inc, RXi Pharmaceuticals Corp

What are the Application segmentation covered in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market report?

Ans: The Applications covered in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market report are Hospital, Clinic, ASCs, Others

What are the Type segmentation covered in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market report?

Ans: The Types covered in the Proliferative Vitreoretinopathy (PVR) Therapeutics Market report are PRM-167, XOMA-089, Others

Recommended Reports

Ophthalmic Devices

Eye Disease Treatments

Pharma Ophthalmic

1 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Overview
1.1 Product Definition
1.2 Proliferative Vitreoretinopathy (PVR) Therapeutics by Type
1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value Comparison by Type (2024 VS 2031)
1.2.2 PRM-167
1.2.3 XOMA-089
1.2.4 Others
1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics by Application
1.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ASCs
1.3.5 Others
1.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue 2020-2031
1.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales 2020-2031
1.4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Competition by Manufacturers
2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2020-2025)
2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Proliferative Vitreoretinopathy (PVR) Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Product Type & Application
2.7 Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Date of Enter into This Industry
2.8 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Competitive Situation and Trends
2.8.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Proliferative Vitreoretinopathy (PVR) Therapeutics Players Market Share by Revenue
2.8.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Scenario by Region
3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2020-2031
3.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2020-2025
3.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2026-2031
3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2020-2031
3.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2020-2025
3.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2026-2031
3.4 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Country
3.4.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2031)
3.4.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Country
3.5.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2031)
3.5.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Region
3.6.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2020-2031)
3.6.3 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2031)
3.7.3 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2031)
3.8.3 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2025)
4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2026-2031)
4.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2020-2031)
4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2025)
4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2026-2031)
4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2020-2031)
4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
5 Segment by Application
5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
5.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2025)
5.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2026-2031)
5.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2020-2031)
5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2025)
5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2026-2031)
5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2020-2031)
5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Company Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Promedior Inc
6.2.1 Promedior Inc Company Information
6.2.2 Promedior Inc Description and Business Overview
6.2.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.2.5 Promedior Inc Recent Developments/Updates
6.3 RXi Pharmaceuticals Corp
6.3.1 RXi Pharmaceuticals Corp Company Information
6.3.2 RXi Pharmaceuticals Corp Description and Business Overview
6.3.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.3.5 RXi Pharmaceuticals Corp Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Chain Analysis
7.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process Analysis
7.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Marketing
7.4.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels
7.4.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
7.5 Proliferative Vitreoretinopathy (PVR) Therapeutics Customer Analysis
8 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Dynamics
8.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
8.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Drivers
8.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Challenges
8.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Proliferative Vitreoretinopathy (PVR) Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Product Type & Application
 Table 12. Global Key Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Proliferative Vitreoretinopathy (PVR) Therapeutics as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2020-2025)
 Table 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2026-2031)
 Table 21. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2020-2025)
 Table 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2026-2031)
 Table 25. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2020-2025)
 Table 53. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2026-2031)
 Table 54. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2020-2025)
 Table 57. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2026-2031)
 Table 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2020-2025)
 Table 63. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2026-2031)
 Table 64. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2020-2025)
 Table 67. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2026-2031)
 Table 68. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Application (2026-2031)
 Table 70. Novartis AG Company Information
 Table 71. Novartis AG Description and Business Overview
 Table 72. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product
 Table 74. Novartis AG Recent Developments/Updates
 Table 75. Promedior Inc Company Information
 Table 76. Promedior Inc Description and Business Overview
 Table 77. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product
 Table 79. Promedior Inc Recent Developments/Updates
 Table 80. RXi Pharmaceuticals Corp Company Information
 Table 81. RXi Pharmaceuticals Corp Description and Business Overview
 Table 82. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product
 Table 84. RXi Pharmaceuticals Corp Recent Developments/Updates
 Table 85. Key Raw Materials Lists
 Table 86. Raw Materials Key Suppliers Lists
 Table 87. Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors List
 Table 88. Proliferative Vitreoretinopathy (PVR) Therapeutics Customers List
 Table 89. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Trends
 Table 90. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Drivers
 Table 91. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Challenges
 Table 92. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Restraints
 Table 93. Research Programs/Design for This Report
 Table 94. Key Data Information from Secondary Sources
 Table 95. Key Data Information from Primary Sources
 Table 96. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Proliferative Vitreoretinopathy (PVR) Therapeutics
 Figure 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type: 2024 & 2031
 Figure 4. PRM-167 Product Picture
 Figure 5. XOMA-089 Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. ASCs
 Figure 12. Others
 Figure 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (2020-2031) & (K Pcs)
 Figure 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Proliferative Vitreoretinopathy (PVR) Therapeutics Report Years Considered
 Figure 18. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Manufacturers in 2024
 Figure 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Proliferative Vitreoretinopathy (PVR) Therapeutics Players: Market Share by Revenue in Proliferative Vitreoretinopathy (PVR) Therapeutics in 2024
 Figure 21. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2020-2031)
 Figure 24. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2020-2031)
 Figure 28. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 36. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Proliferative Vitreoretinopathy (PVR) Therapeutics by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Proliferative Vitreoretinopathy (PVR) Therapeutics by Type (2020-2031)
 Figure 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Proliferative Vitreoretinopathy (PVR) Therapeutics by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Proliferative Vitreoretinopathy (PVR) Therapeutics by Application (2020-2031)
 Figure 61. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart